• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

Latest: Watch here for details of new products and services.

Pharmalicensing
is a division of
UTEK Europe Ltd

— LEUVEN, Belgium, September 19

LEUVEN, Belgium, September 19 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease and cancer announces today its promotion to the Belgian Midcap index (Bel Mid Index or BELMID). After a quarterly review of Belgian indices by Euronext Brussels, ThromboGenics will enter the Bel Mid Index from October 1, 2008.

The elevation of ThromboGenics to the Bel Mid Index reflects the significant progress the Company has made since its IPO in 2006. The Company's lead product, Microplasmin for back of the eye disease has advanced considerably with Phase III trials expected to begin in early 2009. Furthermore, the Company has recently signed a strategic alliance with Roche for its novel anti-cancer antibody for up to EUR 500 million. ThromboGenics has also continued to build and diversify its shareholder base, which is comprised of both domestic and international investors.

Chris Buyse, Chief Financial Officer of ThromboGenics, commenting on today's announcement said: "We are very pleased to have been promoted to the Bel Mid Index. ThromboGenics has undergone a marked progression since its IPO and in recent months has underlined its position as one of the leading Belgian biotechnology companies. Our inclusion in this index will give us greater exposure and access to a wider range of potential investors, which will be of value as we continue to execute our growth strategy."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of eye disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development by the end of 2008, and TB-403 (Anti-PlGF). ThromboGenics and its development partner BioInvent, have recently signed a license agreement with Roche for TB-403 worth up to EUR500 million plus royalties. A Phase Ib clinical trial with TB-403 has recently begun in patients with late stage cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Chris Buyse, CFO Tel : +32-16-75-13-10, chris.buyse@thrombogenics.com ; Patrik De Haes, COO Tel : +32-16-75-13-10, patrik.dehaes@thrombogenics.com ; Desire Collen, Chairman Tel : +32-16-75-13-10, desire.collen@thrombogenics.com . Citigate Dewe Rogerson Amber Bielecka/ David Dible / Nina Enegren Tel: +44(0)207-638-95-71, amber.bielecka@citigatedr.co.uk

• ThromboGenics

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us